Reported 1 day ago
Jim Cramer described Revolution Medicines, Inc. (NASDAQ:RVMD) as a 'speculative situation' during his lightning round segment, acknowledging its focus on developing therapies for RAS-driven cancers. He expressed a personal connection to cancer struggles and emphasized support for speculative stocks in the oncology field. Raymond James recently raised its price target for RVMD due to the promising acceptance of its treatment daraxonrasib into an FDA review process.
Source: YAHOO